PK of Loestrin with VH4524184 in Healthy Females

Phase 1, open-label, single-arm trial of VH4524184 in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Area under the concentration-time curve from time zero to the end of the dosing interval at steady state of EE and NEA without coadministration at Day 10, Area under the concentration-time curve from time zero to the end of the dosing interval at steady state of EE and NEA with coadministration at Day 20 and 2 more. Started Mar 2024; status: completed.